ATTO-3712 / Attovia Therap - LARVOL DELTA

Attovia Therapeutics Announces $90 Million Series C Financing to Advance ATTOBODY-based Programs through Clinical Proof of Concept (GlobeNewswire) - "Attovia Therapeutics...today announced the close of a $90 million Series C financing....Proceeds from the financing, along with the Company’s existing cash and investments, will be used to advance Attovia’s lead assets, ATTO-1310 and ATTO-3712, through clinical proof-of-concept, with the aim of achieving best-in-disease efficacy for the treatment of chronic pruritus and atopic dermatitis....The company plans to start Phase 1 clinical studies with ATTO-3712 in the second half of 2025."

Financing • New P1 trial • Atopic Dermatitis • Pruritus

Attovia Therapeutics Raises $105 Million Oversubscribed Series B Financing Led by Goldman Sachs Alternatives (GlobeNewswire) - "Attovia Therapeutics today announced the closing of a $105 million oversubscribed Series B financing, bringing the total capital raised by the Company since its launch in June 2023 to $165 million. Proceeds from the financing will be used to advance the Company’s lead programs ATTO-1310 and ATTO-002 through initial clinical data readouts, expand the Company’s immunology and inflammation pipeline, and to further develop the ATTOBODY platform....Attovia expects to nominate a development candidate for ATTO-002 in the second half of 2024 and advance the candidate to IND in 2025."

Financing • Pipeline update • Atopic Dermatitis • Immunology